Revance foses first patient in ASPEN phase 3 clinical program of RT002 injectable
Revance Therapeutics announced initiation of patient dosing in the company’s ASPEN Phase 3 clinical program for its investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia, a movement disorder of the neck. June 21, 2018